Crinetics Pharmaceuticals Inc (CRNX)

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of...

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY...

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities

Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education...

Form 4 - Statement of changes in beneficial ownership of securities

Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class...

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

      PALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment...

Form 144 - Report of proposed sale of securities

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors